Literature DB >> 3525407

Mechanisms involved in protection provided by immunization against core lipopolysaccharides of Escherichia coli J5 from lethal Haemophilus pleuropneumoniae infections in swine.

B W Fenwick, J S Cullor, B I Osburn, H J Olander.   

Abstract

In an investigation of the potential protective effects of immunity against common lipopolysaccharide core antigens of gram-negative bacteria during a severe gram-negative infection in the natural host, we induced Haemophilus pleuropneumoniae infections in weanling pigs immunized with a vaccine of an Rc mutant of Escherichia coli (strain J5). To help define the mechanism involved in J5-mediated protection, we compared the clinical, hematologic, bacteriologic, and serologic responses following an H. pleuropneumoniae infection in J5-immunized pigs with those following an H. pleuropneumoniae infection in nonimmunized control animals. As a result of an intranasal inoculation, all of the control animals and the J5-immunized animals were infected with H. pleuropneumoniae. However, while 80% (4 of 5) of the nonimmunized pigs died within 24 h as a result of the infection, no deaths occurred in the J5-immunized animals. In the immunized group, J5 titers dropped during the acute stages of the infection and rebounded to well above the prechallenge levels during convalescence. The J5 titer also increased in the single surviving control animal. These findings suggest that antibodies against common subsurface components of gram-negative bacterial cell walls correlate with protection from an otherwise lethal challenge of H. pleuropneumoniae but do not prevent infection. Important growth-phase-dependent antigenic changes have been recognized to occur during the growth of H. pleuropneumoniae in cultures (R. Nielson, Nord. Veterinaermed. 28:337-348, 1976). In a study of these changes and during an inquiry into the mechanism of J5 antibody-mediated protection, measured quantities of H. pleuropneumoniae were removed from a broth culture at hourly intervals and used to absorb hyperimmune equine J5 antiserum. Significantly greater amounts of J5-specific antibodies were absorbed during the log phase of bacterial growth than during the early or late phase. The availability of epitopes recognized by J5 antibodies appears to be closely related to the rate of bacterial multiplication. The results of these experiments suggest a mechanism of protection provided by increased immunity to E. coli J5 during gram-negative infections.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3525407      PMCID: PMC260874          DOI: 10.1128/iai.53.2.298-304.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  THE BIOSYNTHESIS OF CELL WALL LIPOPOLYSACCHARIDE IN ESCHERICHIA COLI. I. THE BIOCHEMICAL PROPERTIES OF A URIDINE DIPHOSPHATE GALACTOSE 4-EPIMERASELESS MUTANT.

Authors:  A D ELBEIN; E C HEATH
Journal:  J Biol Chem       Date:  1965-05       Impact factor: 5.157

2.  Treatment and prevention of intravascular coagulation with antiserum to endotoxin.

Authors:  A I Braude; H Douglas; C E Davis
Journal:  J Infect Dis       Date:  1973-07       Impact factor: 5.226

3.  Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant.

Authors:  E J Ziegler; H Douglas; J E Sherman; C E Davis; A I Braude
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

4.  Passive immunization against the local Shwartzman reaction.

Authors:  A I Braude; H Douglas
Journal:  J Immunol       Date:  1972-02       Impact factor: 5.422

5.  A proposed mechanism for natural immunity to enterobacterial pathogens.

Authors:  L Chedid; M Parant; F Parant; F Boyer
Journal:  J Immunol       Date:  1968-02       Impact factor: 5.422

6.  [Haemophilus-pleuropneumonia in swine. V. Pathomorphology].

Authors:  H Häni; H König; J Nicolet; E Scholl
Journal:  Schweiz Arch Tierheilkd       Date:  1973-05       Impact factor: 0.845

7.  The plasma protamine paracoagulation test: clinical and laboratory evaluation.

Authors:  W R Kidder; L J Logan; S I Rapaport; M J Patch
Journal:  Am J Clin Pathol       Date:  1972-12       Impact factor: 2.493

8.  Immunization with R mutants of S. Minnesota. I. Protection against challenge with heterologous gram-negative bacilli.

Authors:  W R McCabe
Journal:  J Immunol       Date:  1972-03       Impact factor: 5.422

9.  Prevention of lethal pseudomonas bacteremia with epimerase-deficient E. coli antiserum.

Authors:  E J Ziegler; J A McCutchan; H Douglas; A I Braude
Journal:  Trans Assoc Am Physicians       Date:  1975

10.  Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins).

Authors:  D C Morrison; C G Cochrane
Journal:  J Exp Med       Date:  1974-09-01       Impact factor: 14.307

View more
  16 in total

1.  Optimization and standardization of an enzyme-linked immunosorbent assay protocol for serodiagnosis of Actinobacillus pleuropneumoniae serotype 5.

Authors:  Y L Trottier; P F Wright; S Larivière
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

Review 2.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

Review 3.  Bacteraemia in man and animals: an overview.

Authors:  J Vaid
Journal:  Vet Res Commun       Date:  1991       Impact factor: 2.459

4.  Blood gas and hematological changes in experimental peracute porcine pleuropneumonia.

Authors:  A L Kiorpes; P S MacWilliams; D I Schenkman; L R Bäckström
Journal:  Can J Vet Res       Date:  1990-01       Impact factor: 1.310

5.  Actinobacillus pleuropneumoniae hlyX gene homology with the fnr gene of Escherichia coli.

Authors:  J I MacInnes; J E Kim; C J Lian; G A Soltes
Journal:  J Bacteriol       Date:  1990-08       Impact factor: 3.490

6.  Convalescent pigs are protected completely against infection with a homologous Actinobacillus pleuropneumoniae strain but incompletely against a heterologous-serotype strain.

Authors:  T Cruijsen; L A van Leengoed; M Ham-Hoffies; J H Verheijden
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

7.  Prevention of clinical coliform mastitis in dairy cows by a mutant Escherichia coli vaccine.

Authors:  R N González; J S Cullor; D E Jasper; T B Farver; R B Bushnell; M N Oliver
Journal:  Can J Vet Res       Date:  1989-07       Impact factor: 1.310

8.  Evaluation of multicomponent recombinant vaccines against Actinobacillus pleuropneumoniae in mice.

Authors:  Meili Shao; Yong Wang; Chunlai Wang; Yang Guo; Yonggang Peng; Jiandong Liu; Guangxing Li; Huifang Liu; Siguo Liu
Journal:  Acta Vet Scand       Date:  2010-09-11       Impact factor: 1.695

9.  Efficacy of a cell extract from Actinobacillus (Haemophilus) pleuropneumoniae serotype 1 against disease in swine.

Authors:  P J Fedorka-Cray; M J Huether; D L Stine; G A Anderson
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

10.  Tissue reaction and immunity in swine immunized with Actinobacillus pleuropneumoniae vaccines.

Authors:  P J Willson; A Rossi-Campos; A A Potter
Journal:  Can J Vet Res       Date:  1995-10       Impact factor: 1.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.